



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 009-001-R44S**ATG13 protein-GST fusion****Overview**

Description:	ATG13 recombinant protein-GST fusion protein - 009-001-R44S
Item No.:	009-001-R44S
Size:	20 µg
Origin:	Human
Expressed in:	E. coli

Product Details

Background: ATG13 is a protein that is part of the autophagy complex which is the major route by which cytoplasmic contents are delivered to the lysosome for degradation. ATG13 localizes on the autophagic isolation membrane and is essential for autophagosome formation. In mammals, ATG13 interacts with ATG1 (ULK1/2) and FIP200 to form the autophagy. ATG101 can also bind to ATG13 protein and is important for the stability and basal phosphorylation of ATG13 and ULK1 (1). mTOR can suppress the autophagy process through direct regulation of the ULK1-Atg13-FIP200 complex where mTOR has been shown to phosphorylate ATG13 (2). ATG13 Protein is ideal for investigators involved in Signaling Proteins, Apoptosis Proteins, Angiogenesis, Angiogenesis, Apoptosis/Autophagy, Apoptosis/Autophagy, Cardiovascular Disease, Cardiovascular Disease, Cellular Stress, Cellular Stress, Inflammation, Inflammation, Metabolic Disorder, Metabolic Disorder, Neurobiology, Neurobiology, NfκB Pathway, NfκB Pathway, p38 Pathway, and p38 Pathway research.

Synonyms:	KIAA0652, Autophagy-related protein 13, ATG13
Species of Origin:	Human
Expressed in:	E. coli
Type:	Recombinant Protein

Target Details

Gene Name:	ATG13
Purity/Specificity:	Recombinant full-length human ATG13 was expressed by baculovirus in E.coli using an N-Terminal Glutathione-S-Transferase fusion protein. The purity was determined to be >70% by densitometry.

- Relevant Links:**
- [009-001-R44 SDS](#)
 - [NCBI - NM_001142673](#)

Application Details

Application Note:	ATG13 Protein is stored in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. ATG13 Protein is suitable for use in Western Blot. Expect a band approximately ~ 96kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
WB:	User Optimized

Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	0.1 µg/µL
Buffer:	See application note.

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Expiration:	Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

www.rockland.com
tech@rockland.com
+1 484.791.3823